BA
ANIX icon

Bard Associates’s Anixa Biosciences ANIX Stock Holding History

Bard Associates’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-51,200
Closed -$59K – 180
2017
Q2 		$59K Hold
51,200
– – 0.03% 173
2017
Q1 		$154K Hold
51,200
– – 0.07% 160
2016
Q4 		$276K Sell
51,200
-1,600
-3% -$8.88K 0.13% 130
2016
Q3 		$205K Sell
52,800
-3,200
-6% -$10.7K 0.1% 149
2016
Q2 		$176K Sell
56,000
-4,800
-8% -$14.6K 0.09% 149
2016
Q1 		$183K Hold
60,800
– – 0.11% 140
2015
Q4 		$183K Hold
60,800
– – 0.11% 135
2015
Q3 		$289K Buy
+60,800
New +$283K 0.17% 119

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DIA
Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CAM
Concorde Asset Management Ann Arbor, Michigan $204M AUM
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bard Associates's ANIX Position: Q3 2017 in Review

Bard Associates sold out of Anixa Biosciences (ANIX) in Q3 2017, closing a stake of 51,200 shares — an estimated $59K sold.

Bard Associates first reported a position in ANIX in Q3 2015 and held it in 8 quarters. The position peaked at $289K in Q3 2015. 20 funds tracked by Wall St. Rank hold ANIX as of Q3 2017.

  • Bard Associates reported no remaining Anixa Biosciences position as of Q3 2017 after selling out during the quarter.
  • Bard Associates sold 51,200 Anixa Biosciences shares in Q3 2017, an estimated $59K.
  • Bard Associates first reported a position in Anixa Biosciences in Q3 2015 and held it in 8 quarters.
  • Bard Associates's Anixa Biosciences position peaked at $289K in Q3 2015.
  • 20 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2017.

Based on Bard Associates's 13F filing for Q3 2017, filed 14 Nov 2017.